text: Could a decades-old malaria drug work to treat COVID-19? Elon Musk seems to think so, recently tweeting that it "might be worth considering chloroquine" for COVID-19. Although data are spare, studies so far seem to back up the billionaire entrepreneur’s suggestion.
  Chloroquine, or hydroxychloroquine, has been used to treat malaria since 1944. It can be given before exposure to malaria to prevent infection, and it can also be given as treatment afterward.
  Malaria is a disease that is caused by a parasite, unlike COVID-19. Nevertheless, laboratory studies show chloroquine is effective at preventing as well as treating the virus that causes severe acute respiratory syndrome, or SARS, a close cousin of COVID-19.
  Tune into ABC at 1 p.m. ET and ABC News Live at 4 p.m. ET every weekday for special coverage of the novel coronavirus with the full ABC News team, including the latest news, context and analysis.
  Given chloroquine’s effectiveness in treating SARS, scientists have investigated if it will be an effective treatment against the new coronavirus responsible for COVID-19. So far, the initial trials are encouraging.
  "There is evidence that chloroquine is effective when they looked at SARS in vitro with primate cells," said Dr. Len Horovitz, a pulmonologist and internist at Lenox Hill Hospital in New York City. "The theory of the experiment with primate cells was that chloroquine could be for preventing viral infection or as a treatment for viral infection after it had occurred. In vitro in these primate cells, there was evidence that viral particles were significantly reduced when chloroquine was used."
  People become infected when those protein spikes bind to special receptors on the outside of human cells. Chloroquine works by interfering with those receptors, which may interfere with the virus’s ability to bind to cells.
  "The way that it worked against SARS was by preventing of the attachment of the virus to the cells. Chloroquine interfered with the attachment to that receptor on the cell membrane surface," Horovitz said. "So it’s disrupting a lock and key kind of mechanism of attachment."
  Researchers in China found that treating patients with COVID-19-associated pneumonia with chloroquine may shorten their hospital stay and improve the patient’s outcome.
  There are more than 20 ongoing clinical trials in China and more scheduled to start in England, Thailand, South Korea and the United States.
  While the U.S. waits for the results of additional trials and FDA approval, researchers caution that doctors should only prescribe the drug for their patients under a special program that allows exceptions for experimental drugs during public health emergencies, under a framework set up by the World Health Organization.
  "For the 85% of patients with mild to moderate symptoms that will go home, they don’t need this treatment and don’t want this treatment – it’s not valuable to them, it doesn’t offer any benefit," said Dr. Cioe-Pena. "There could be minimal risk, but still risk. Risk of an allergic reaction is really a risk of a side effect, and they are going to get better anyway."
  Thankfully, the potential side effects of the drug are minimal.
  "The principle side effects reported were headaches, gastrointestinal side effects like nausea, diarrhea and hair loss, primarily," said Horovitz.
  In addition, pharmaceutical company Bayer announced Thursday that it is donating 3 million tablets of the drug Resochin (chloroquine phosphate), a product discovered by the company in 1934 that is indicated for prevention and treatment of malaria, to the U.S. government.
  Resochin also appears to have broad spectrum antiviral properties and effects on the body’s immune response, and new clinical research out of China shows potential for it to treat patients with COVID-19 infection, according to a statement from Bayer.
  The drug is currently not approved for use in the U.S., but Bayer is working with the appropriate agencies on an Emergency Use Authorization.
  More encouraging still is that there are several other promising drugs being studied, including the HIV anti-retroviral drug Kaletra (lopinavir/ritonavir) and the anti-Ebola medication remdesivir.
  In the meantime we should each do our part by engaging in social distancing, self-quarantining and self-isolating when appropriate, to stop the spread of this pandemic.
  Angela N. Baldwin, M.D., M.P.H., is a pathology resident at Montefiore Health System in the Bronx and a contributor to the ABC News Medical Unit